Comparative Pharmacology
Head-to-head clinical analysis: LO OVRAL 28 versus MODICON 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LO OVRAL 28 versus MODICON 21.
LO/OVRAL-28 vs MODICON 21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of norgestrel, a progestin, and ethinyl estradiol, an estrogen; suppresses gonadotropin secretion (FSH and LH) primarily via progestational activity, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial development, reducing implantation likelihood.
Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) from pituitary via negative feedback, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; induces endometrial thinning.
One tablet orally once daily for 28 days. Each tablet contains 0.3 mg norgestrel and 0.03 mg ethinyl estradiol. Active tablets (21 days) followed by placebo tablets (7 days).
One tablet (norethindrone 0.5 mg and ethinyl estradiol 0.035 mg) orally once daily for 21 consecutive days, followed by 7 drug-free days.
None Documented
None Documented
Norgestrel: 20-40 hours; Ethinyl estradiol: 13-27 hours. Steady-state achieved after 3-5 half-lives.
Terminal elimination half-life: 12–18 hours; clinical context: steady-state reached after 3–5 days of daily dosing
Renal (approx. 50% as metabolites, <1% unchanged); biliary/fecal (approx. 50% as metabolites).
Renal (80% as metabolites, 20% unchanged); biliary/fecal (minor, <5% total)
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive